Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy

Current Oncology Reports

Volumn 12, Issue 6, 2010, Pages 383-394

  Evens, Andrew M ^a,b   Roy, Rupali ^a,b   Sterrenberg, Danielle ^a   Moll, Michelle Z ^a,b   Chadburn, Amy ^a,c   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NW Univ Feinberg School of Medicine   (United States)

^c Department of Pathology ^*  (United States)

Author keywords

Lymphoma; Post transplantation complications; Prognosis; Rituximab; Solid organ transplant; Treatment

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARGININE BUTYRATE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GROWTH FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TEMSIROLIMUS; THYMIDINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; REED STERNBERG CELL; REMISSION; RETREATMENT; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; MORBIDITY; ORGAN TRANSPLANTATION; RISK FACTORS; SURVIVAL RATE; T-LYMPHOCYTES; TISSUE TRANSPLANTATION; TREATMENT OUTCOME;

EID: 78649905197     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0132-1     Document Type: Review

References (65)

1. I Penn W Hammond L Brettschneider TE Starzl 1969 Malignant lymphomas in transplantation patients Transplant Proc 1 106 112 1:STN:280: DyaE38%2FosFCgsw%3D%3D 4944206
2. • Ghobrial IM, Habermann TM, Maurer MJ, et al.: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005, 23:7574-7582. This is one of the largest PTLD series reported to date; the authors studied 107 patients over a 33-year period.
3. V Leblond N Dhedin 2001 Mamzer Bruneel MF, et al.: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders J Clin Oncol 19 772 778 1:STN:280:DC%2BD3M7kvV2ltQ%3D%3D 11157030
4. BP Nelson MA Nalesnik DW Bahler, et al. 2000 Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24 375 385 1:STN:280:DC%2BD3c7nvVyqtw%3D%3D 10716151 10.1097/00000478- 200003000-00006 (Pubitemid 30127473)
5. • Evens AM, David KA, Helenowski I, et al.: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010, 28:1038-1046. This is a multicenter analysis of 80 PTLD patients treated over a recent 10-year period. There appeared to be significantly improved OS from early rituximab-based therapy.
6. •• Trappe R CS, Oertel S: Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD: Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial. Blood 2009, 100a. This is a recent presentation of a large prospective multicenter PTLD analysis that utilized early rituximab-based therapy. One-year PFS was 93% using risk-stratified therapy using R-CHOP for patients who did not achieve CR to 4 weeks of rituximab.
7. AW Loren DL Porter EA Stadtmauer DE Tsai 2003 Post-transplant lymphoproliferative disorder: a review Bone Marrow Transplant 31 145 155 1:STN:280:DC%2BD3s7gslyhsQ%3D%3D 12621474 10.1038/sj.bmt.1703806 (Pubitemid 36305567)
8. MF Mamzer-Bruneel C Lome E Morelon, et al. 2000 Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center J Clin Oncol 18 3622 3632 1:CAS:528:DC%2BD3cXot1antr0%3D 11054435
9. V Leblond F Davi F Charlotte, et al. 1998 Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16 2052 2059 1:STN:280:DyaK1c3ovFCnsQ%3D%3D 9626203
10. G Dotti R Fiocchi T Motta, et al. 2002 Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome Transplantation 74 1095 1102 12438953 10.1097/00007890-200210270-00007
11. RL Elstrom C Andreadis NA Aqui, et al. 2006 Treatment of PTLD with rituximab or chemotherapy Am J Transplant 6 569 576 1:CAS:528: DC%2BD28Xit12gt7k%3D 16468968 10.1111/j.1600-6143.2005.01211.x (Pubitemid 43382145)
12. • Knight J, Tsodikov A, Cibrik D, et al.: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009, 27:1-12. The authors examined 7040 patients who received SOT from 1964 to 2007, from which 78 patients developed PTLD. They assessed risk factors for development of PTLD and compared outcomes with a SEER population sample.
13. • Maecker B, Jack T, Zimmermann M, et al.: CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007, 25:4902-4908. A total of 55 pediatric PTLD patients were studied. The 5-year EFS and OS were 59% and 68%, respectively.
14. RA McDonald JM Smith M Ho, et al. 2008 Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids Am J Transplant 8 984 989 1:STN:280: DC%2BD1c3ls1GrtA%3D%3D 18416737 10.1111/j.1600-6143.2008.02167.x (Pubitemid 351537758)
15. G Opelz B Dohler 2004 Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 222 230 14974943 10.1046/j.1600-6143.2003.00325.x (Pubitemid 38248525)
16. VR Dharnidharka EK Sullivan DM Stablein, et al. 2001 Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Transplantation 71 1065 1068 1:STN:280: DC%2BD3M3ptFOgtg%3D%3D 11374404 10.1097/00007890-200104270-00010
17. SM Cockfield 2001 Identifying the patient at risk for post-transplant lymphoproliferative disorder Transpl Infect Dis 3 70 78 1:STN:280: DC%2BD3MzivV2ktA%3D%3D 11395972 10.1034/j.1399-3062.2001.003002070.x (Pubitemid 32452921)
18. DE Tsai CL Hardy JE Tomaszewski, et al. 2001 Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients Transplantation 71 1076 1088 1:CAS:528:DC%2BD3MXktleltrY%3D 11374406 10.1097/00007890-200104270-00012
19. S Caillard V Dharnidharka L Agodoa, et al. 2005 Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression Transplantation 80 1233 1243 1:CAS:528:DC%2BD2MXht1Gru7nP 16314791 10.1097/01.tp.0000179639.98338.39 (Pubitemid 41746802)
20. AB Oton H Wang X Leleu, et al. 2008 Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant Leuk Lymphoma 49 1738 1744 1:CAS:528: DC%2BD1cXhtFant73I 18798108 10.1080/10428190802239162
21. • Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007, 92:1489-1494. This is a prospective phase 2 trial of single-agent rituximab after failure of RI. The initial ORR was 79% with 34% CR; 3-year OS was approximately 58%.
22. I Penn G Porat 1995 Central nervous system lymphomas in organ allograft recipients Transplantation 59 240 244 1:STN:280:DyaK2M7ktFeqsg%3D%3D 7839447
23. • Swerdlow SH CE, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, edn 4. Lyon, France: International Agency for Research on Cancer; 2008. This is an updated comprehensive WHO classification of pathology of PTLD.
24. DM Knowles E Cesarman A Chadburn, et al. 1995 Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders Blood 85 552 565 1:CAS:528:DyaK2MXjtVWhsr8%3D 7812011
25. A Chadburn E Cesarman DM Knowles 1997 Molecular pathology of posttransplantation lymphoproliferative disorders Semin Diagn Pathol 14 15 26 1:STN:280:DyaK2s7pslCntA%3D%3D 9044506
26. L Novoa-Takara SL Perkins D Qi, et al. 2005 Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation Am J Clin Pathol 45 313 318
27. M Djokic MM Le Beau LJ Swinnen, et al. 2006 Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities Genes Chromosomes Cancer 45 313 318 1:CAS:528:DC%2BD28Xht1Ohsb4%3D 16283619 10.1002/gcc.20287 (Pubitemid 43238481)
28. A Rinaldi D Capello M Scandurra, et al. 2010 Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma Br J Haematol 149 569 577 1:CAS:528: DC%2BC3cXns1eqt7Y%3D 20230398 10.1111/j.1365-2141.2010.08125.x
29. LR Johnson MA Nalesnik SH Swerdlow 2006 Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study Am J Surg Pathol 30 1604 1612 17122518 10.1097/01.pas.0000213317.59176.d2 (Pubitemid 44808798)
30. FE Craig LR Johnson SA Harvey, et al. 2007 Gene expression profiling of Epstein-Barr viruspositive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders Diagn Mol Pathol 16 158 168 1:CAS:528: DC%2BD2sXhtVKhu7jK 17721324 10.1097/PDM.0b013e31804f54a9 (Pubitemid 47329876)
31. HE Heslop 2009 How I treat EBV lymphoproliferation Blood 114 4002 4008 1:CAS:528:DC%2BD1MXhsVGku73F 19724053 10.1182/blood-2009-07-143545
32. TE Starzl MA Nalesnik KA Porter, et al. 1984 Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 583 587 1:STN:280:DyaL2c7ktVOntA%3D%3D 6142304 10.1016/S0140-6736(84) 90994-2
33. LJ Swinnen GM Mullen TJ Carr, et al. 1995 Aggressive treatment for postcardiac transplant lymphoproliferation Blood 86 3333 3340 1:CAS:528:DyaK2MXovFahs7k%3D 7579436
34. S Choquet V Leblond R Herbrecht, et al. 2006 Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study Blood 107 3053 3057 1:CAS:528:DC%2BD28Xjs1Olurs%3D 16254143 10.1182/blood-2005-01-0377
35. M Benkerrou JP Jais V Leblond, et al. 1998 Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome Blood 92 3137 3147 1:CAS:528: DyaK1cXntFCqsLg%3D 9787149
36. CL Davis BL Wood DE Sabath, et al. 1998 Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants Transplantation 66 1770 1779 1:CAS:528:DyaK1MXmvFejsQ%3D%3D 9884275 10.1097/00007890-199812270-00035 (Pubitemid 29035007)
37. E Haddad S Paczesny V Leblond, et al. 2001 Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial Blood 97 1590 1597 1:CAS:528:DC%2BD3MXitFalt78%3D 11238096 10.1182/blood.V97.6.1590 (Pubitemid 32217222)
38. S Choquet R Trappe V Leblond, et al. 2007 CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation Haematologica 92 273 274 17296588 10.3324/haematol.10595 (Pubitemid 46852438)
39. C Fohrer S Caillard A Koumarianou, et al. 2006 Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen Br J Haematol 134 602 612 1:CAS:528:DC%2BD28XhtFSgsLbL 16889621 10.1111/j.1365-2141.2006.06228.x (Pubitemid 44253602)
40. JD Pirsch RJ Stratta HW Sollinger, et al. 1989 Treatment of severe Epstein-Barr virusinduced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation Am J Med 86 241 244 1:STN:280: DyaL1M7hs1alsw%3D%3D 2536518 10.1016/0002-9343(89)90279-9 (Pubitemid 19049642)
41. W Schmidt I Anagnostopoulos H Scherubl 2000 Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient N Engl J Med 342 440 441 1:STN:280:DC%2BD3c7hs12lug%3D%3D 10681228 10.1056/NEJM200002103420617 (Pubitemid 30084549)
42. SH Oertel MS Ruhnke I Anagnostopoulos, et al. 1999 Treatment of Epstein-Barr virusinduced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation Transplantation 67 765 767 1:STN:280:DyaK1M7psVajsA%3D%3D 10096538 10.1097/00007890-199903150-00023
43. DP Funch AM Walker G Schneider, et al. 2005 Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients Am J Transplant 5 2894 2900 1:STN:280: DC%2BD2MnitFKmtg%3D%3D 16303002 10.1111/j.1600-6143.2005.01115.x (Pubitemid 43923949)
44. SV McDiarmid S Jordan GS Kim, et al. 1998 Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients Transplantation 66 1604 1611 1:STN:280:DyaK1M%2FpvVOitw%3D%3D 9884246 10.1097/00007890-199812270-00006 (Pubitemid 29034978)
45. JF Buell TG Gross MJ Hanaway, et al. 2005 Posttransplant lymphoproliferative disorder: significance of central nervous system involvement Transplant Proc 37 954 955 1:STN:280:DC%2BD2M3hsV2gsQ%3D%3D 15848587 10.1016/j.transproceed.2004.12.130 (Pubitemid 40590756)
46. S Caillard C Lelong F Pessione B Moulin 2006 Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry Am J Transplant 6 2735 2742 1:STN:280:DC%2BD28nhs1CltQ%3D%3D 17049061 10.1111/j.1600-6143.2006.01540.x (Pubitemid 44571695)
47. • Cavaliere R, Petroni G, Lopes MB, Schiff D: Primary central nervous system posttransplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010, 116:863-870. This is an analysis of 34 primary CNS PTLD patients treated over a 25-year period. Median OS was 47 months. Treatment with aggressive therapy, similar to immunocompetent primary CNS, is recommended (eg, high-dose methotrexate-based therapy).
48. Choquet S OS, Anagnostopoulos I, et al.: Results of the largest study on post-transplantlymphoproliferations (PTLDs) of the central nervous system (CNS) in the rituximab era: a surprising overrepresentation of kidney transplantations, key importance of methotrexate, cytarabine and radiotherapy for long term survival and low impact of rituximab. Blood (ASH Annual Meeting Abstracts) 2008, 3614.
49. Evens AM, Smith SM: Reply to D. Dierickx et al. J Clin Oncol 2010, In press.
50. Moise L MC, Pilorge S, et al.: High-dose methotrexate and cytarabine chemotherapy may be effective and safe in solid organ transplant recipients with primary CNS lymphomas (PCNSL). Blood (ASH Annual Meeting Abstracts) 2008, 3611.
51. MM Taj B Messahel J Mycroft, et al. 2008 Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children Br J Haematol 140 191 196 1:CAS:528:DC%2BD1cXitVOntL0%3D 18173755 10.1111/j.1365-2141.2007. 06896.x (Pubitemid 350265042)
52. MA Nalesnik AS Rao H Furukawa, et al. 1997 Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients Transplantation 63 1200 1205 1:CAS:528:DyaK2sXjs1Kmt7w%3D 9158009 10.1097/00007890-199705150-00002 (Pubitemid 27212810)
53. Y Fujita CM Rooney HE Heslop 2008 Adoptive cellular immunotherapy for viral diseases Bone Marrow Transplant 41 193 198 1:CAS:528:DC%2BD1cXhs1yms70%3D 17982497 10.1038/sj.bmt.1705906 (Pubitemid 351188917)
54. A Moosmann I Bigalke J Tischer, et al. 2010 Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells Blood 115 2960 2970 1:CAS:528:DC%2BC3cXkvFKhs7w%3D 20103780 10.1182/blood-2009-08-236356
55. •• Haque T, Wilkie GM, Jones MM, et al.: Allogeneic cytotoxic T-cell therapy for EBVpositive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131. This multicenter study used EBV-specific partial allogeneic-matched cytotoxic T cells generated from EBV-positive donors for the treatment of EBV-positive PTLD. ORR at 6 months was 52%, including 42% CR rate. Therapy was overall well-tolerated.
56. J Brewin C Mancao K Straathof, et al. 2009 Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease Blood 114 4792 4803 1:CAS:528:DC%2BD1MXhsFGqsbzO 19770360 10.1182/blood-2009-07-228387
57. B De Angelis G Dotti C Quintarelli, et al. 2009 Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) Blood 114 4784 4791 19759356 10.1182/blood-2009-07-230482
58. SJ Mentzer SP Perrine DV Faller 2001 Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate Transpl Infect Dis 3 177 185 1:STN:280:DC%2BD3MvntVCqtg%3D%3D 11493400 10.1034/j.1399-3062.2001. 003003177.x (Pubitemid 32756700)
59. • Perrine SP, Hermine O, Small T, et al.: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109:2571-2578. This is a prospective clinical trial using concurrent ganciclovir and arginine butyrate therapy; the latter was utilized in order to upregulate thymidine kinase. An ongoing related clinical trial is referenced below.
60. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00992732?term= arginine+butyrate&rank=5. Accessed August 2010.
61. M Majewski M Korecka P Kossev, et al. 2000 The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders Proc Natl Acad Sci U S A 97 4285 4290 1:CAS:528:DC%2BD3cXislSnsro%3D 10759564 10.1073/pnas.080068597 (Pubitemid 30226125)
62. Smith SM, van Besien K, Karrison T et al.: Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. J Clin Oncol. 2010 Sep 13. [Epub ahead of print].
63. AD Kirk WS Cherikh M Ring, et al. 2007 Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant 7 2619 2625 1:CAS:528: DC%2BD2sXhtlakt73F 17868060 10.1111/j.1600-6143.2007.01972.x (Pubitemid 47561615)
64. IM Ghobrial TM Habermann KM Ristow, et al. 2005 Prognostic factors in patients with posttransplant lymphoproliferative disorders (PTLD) in the rituximab era Leuk Lymphoma 46 191 196 1:CAS:528:DC%2BD2cXhtFSntrnI 15621801 10.1080/10428190400012011 (Pubitemid 40185948)
65. AB Jain A Marcos R Pokharna, et al. 2005 Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center Transplantation 80 1692 1698 1:CAS:528:DC%2BD2MXhtlCksL%2FE 16378063 10.1097/01.tp.0000185570.41571.df (Pubitemid 43053993)